Skip to main content

Table 1 A selection of APOE based therapeutics used in rodent models and and clinical testing

From: Therapeutic approaches targeting Apolipoprotein E function in Alzheimer’s disease

DrugRationaleDeveloped byReference/Clinical Trial Identifier
CS-6253Increase APOE lipidation by activating ABCA1Tel Aviv University/Artery TherapeuticsRef 125
CN-105APOE mimeticCereNova/AegisCN LLCPhase1: NCT02670824 (ICH); Ref 231
Phthalazinones, pyrazolinesSmall molecule structure-correctorsGladstone Institute/E-Scape bioRef 132
APOE antibodyTargeting non-lipidated APOEWashington University/Denali therapeuticsRef 99
Anti-sense oligonucleotideReduce expression of APOE4Washington University/IonisRef 104
Gene TherapyBiological: AAVrh.10 hAPOE2 vectorCornell UniversityPhase 1: NCT03634007
BexaroteneAlter APOE production, APOE lipidation and Aβ clearanceReXceptor Inc. and C2NPhase 1: NCT02061878
Outcome: No change in Aβ; increased CSF APOE
Cleveland ClinicPhase 2:NCT01782742
Outcome: No benefit in APOE4 patients; Ref 114
ProbucolCholesterol lowering drugMcGill University/Douglas Hospital Research CenterPhase1/2: NCT02707458 Ref 232
AGB101Reduce APOE4-dependent abnormal hippocampal network activityMedical College of WisconsinPhase 2: NCT03461861 Ref 233
RosiglitazoneAnti-diabetic (APOE allele dependent response)GlaxoSmithKlinePhase3: NCT00348140
Outcome:No effect on mild to moderate AD;
Ref 234
Epigallocatechin gallate (EGCG) + multimodal intervention (diet, exercise)Correct APOE4-dependent cognitive declineParc de Salut MarRecruiting: NCT03978052. No direct references found but see Ref 235
ExerciseRelationship of APOE4 to CBF and blood-based biomarkers (IGF-1, VEGF, BDNF)University of Kansas Medical CenterRecruiting:
NCT04009629
Ref 236